Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Performance Study to Validate the Use of Novel Molecular Diagnostic Assays for the Detection of Cancer Biomarkers in Peripheral Blood and Primary Tumor Tissue of Patients With Recurrent/Metastatic HNSCC, NSCLC or Melanoma.

NCT04490564 is registered in ClinicalTrials.gov with Pharmassist Ltd as lead sponsor.

NCT NCT04490564
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04490564 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Performance Study to Validate the Use of Novel Molecular Diagnostic Assays for the Detection of Cancer Biomarkers in Peripheral Blood and Primary Tumor Tissue of Patients With Recurrent/Metastatic HNSCC, NSCLC or Melanoma.
Lead sponsor
Pharmassist Ltd
Phase
Observational
Overall status
Completed
Start date
June 25, 2019
Completion date
September 7, 2022
Enrollment
135 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck squamous cell carcinoma, melanoma, non small cell lung cancer